Genomtec

Genomtec Net Change in Cash

The Net Change in Cash of Genomtec (GMT.WA) as of Oct 15, 2026 is -1.98 M PLN. In the previous year, Net Change in Cash was 2.53 M PLN — a change of -178.13% (lower).

Net Change in Cash

-1.98 MPLN

YoY

-178.13%

Last updated:

Net Change in Cash of Genomtec is 2025 -1.98 M PLN. Net Change in Cash of Genomtec was 2024 2.53 M PLN. It decreases by -178.13% lower compared to the previous year.

The Genomtec Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2019
1.08 M PLN
Jan 1, 2020
5.88 M PLN
Jan 1, 2021
-5.92 M PLN
Jan 1, 2022
2.76 M PLN
Jan 1, 2023
41,999.00 PLN
Jan 1, 2024
2.53 M PLN
Jan 1, 2025
-1.98 M PLN
The Genomtec Net Change in Cash history
YEARNet Change in CashYoY
-1.98 MPLN-178.13%
2.53 MPLN+5,919.19%
41,999.00PLN-98.48%
2.76 MPLN-146.57%
-5.92 MPLN-200.68%
5.88 MPLN+443.75%
1.08 MPLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genomtec Stock analysis

What does Genomtec do? Genomtec SA is a company based in Wrocław, Poland, listed on the Warsaw Stock Exchange under the ticker GMT.WA. It has an ISIN code of PLGNMTC00017 and went public through an IPO on March 17, 2021. The company operates in the field of molecular diagnostics, focusing on the research and development of diagnostic equipment. Genomtec SA is known for developing the Genomtec ID platform, a mobile solution designed for genetic diagnosis at the point of patient care. This platform enables diagnostic procedures to be conducted in settings such as primary care clinics, pharmacies, doctor’s offices, and hospital emergency departments without requiring complex laboratory workflows or specialized personnel. The company's technology aims to streamline the diagnostic process, making it more accessible and efficient in various healthcare environments. Genomtec SA's headquarters are located in Wrocław, within the Lower Silesian Voivodeship. The company's website is https://genomtec.com/, where further information about its products and services can be found. As of the available information, Genomtec SA is active in the development and commercialization of its mobile diagnostic platform, targeting healthcare providers seeking to integrate rapid genetic testing into their practice. The company does not specify its sector or industry in the provided data, but it is clearly engaged in medical technology innovation. Genomtec is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genomtec stock

Net Change in Cash of Genomtec is -1.98 M PLN in 2025.

Net Change in Cash of Genomtec changed from 2.53 M PLN to -1.98 M PLN, representing a -178.13% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Genomtec since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Genomtec historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Genomtec

All Key Metrics — Genomtec